Phase III Study to Evaluated Morning Testosterone Normalization in Overweight Men Less Than 60 Years of Age With Secondary Hypogonadism

This study has been completed.
Information provided by (Responsible Party):
Repros Therapeutics Inc. Identifier:
First received: November 29, 2012
Last updated: October 22, 2013
Last verified: October 2013

The purpose of ZA-302 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T<300 ng/dL) and normal sperm concentration, compared to changes with placebo. Subjects must not have previously been treated with testosterone products within the last 6 months.

Condition Intervention Phase
Secondary Hypogonadism
Low Testosterone
Drug: enclomiphene citrate
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration

Resource links provided by NLM:

Further study details as provided by Repros Therapeutics Inc.:

Primary Outcome Measures:
  • Change in morning testosterone [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Proportion of subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment. Cavg will be calculated as the numerical average of 24-hour serial testosterone assessments at 0, 1, 2, 3, 4, 8, 12, 16 and 24 hours after dosing.

  • Change in sperm concentration [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Proportion of subjects with a 50% or greater decrease in sperm concentration from baseline after 12 weeks of treatment

Enrollment: 181
Study Start Date: November 2012
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Androxal 12.5 mg
Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
Drug: enclomiphene citrate
oral, capsules, taken one time daily, for 3 months
Other Name: Androxal
Experimental: Androxal 25 mg
Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
Drug: enclomiphene citrate
oral, capsules, taken one time daily, for 3 months
Other Name: Androxal
Placebo Comparator: Placebo
Placebo oral capsules taken one time daily
Drug: Placebo
Oral capsule taken one time daily for 3 months

Detailed Description:

Protocol ZA-302 is a randomized, double-blind, placebo-controlled multi-center Phase 3 study to evaluate normalization of morning testosterone levels in overweight men with acquired hypogonadotropic hypogonadism and normal baseline sperm concentrations. The study requires 10 to 12 clinic visits (2 for eye exams), and is approximately 4 to 5½ months in duration. Subjects will be treated for 12-18 weeks. At Visit 3 (Week 6) subjects who do not achieve morning T values ≥300 ng/dL will be up-titrated to 25 mg. Placebo subjects may be sham titrated. Up-titrated subjects will receive an additional 6 weeks of treatment (18 weeks total). A schedule of procedures and assessments is displayed in Section 4. The study will enroll up to 152 male subjects, up to 114 randomized to treatment with Androxal and up to 38 randomized to placebo, in a 3:1 ratio. Subjects must not have used any prior testosterone treatments within the last 6 months.

Eligible subjects must have 2 consecutive assessments of morning T below 300 ng/dL and LH below 9.4 mIU/mL. They will provide 2 sperm samples at baseline, at least 2 days apart, another 2 after 12 weeks of treatment, and up-titrated subjects will provide an additional 2 samples at the end of treatment. After 12 weeks of treatment (V5) all subjects will undergo serial T assessment for determination of the Cavg. Safety assessments will include collection of adverse events, eye examinations, physical examinations and clinical laboratory assessments.


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Overweight (BMI 25 to 42 kg/m2 inclusive) males age 18 to 60 inclusive
  2. All clinical laboratory tests within normal ranges (any clinically significant deviation of laboratory results will require approval of sponsor)
  3. Previously or concurrently diagnosed as having secondary hypogonadism characterized as having 2 consecutive morning testosterone assessments < 300ng/dL, one of which must be confirmed at Baseline.
  4. LH < 9.4 mIU/mL (at Visit 1 only)
  5. Sperm count ≥ 15 million per milliliter (assessed twice at least 48 hours apart)
  6. Ability to complete the study in compliance with the protocol
  7. Ability to understand and provide written informed consent
  8. Agreement to provide a total of up to 6 semen sample in a sponsor-approved clinic on up to 6 separate occasions.

Exclusion Criteria:

  1. Any prior use of testosterone treatments within the last 6 months
  2. Use of spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study
  3. Use of Clomid in the past year
  4. Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study. Newly diagnosed diabetics need to be treated for at least 48 hours before being enrolled in the study.
  5. Clinically significant abnormal findings at Screening (Visit 1) or Baseline, based on the Investigator's assessment
  6. A hematocrit >54% or a hemoglobin >17 g/dL (sponsor may approve enrollment of subjects with hemoglobin up to 17.5 g/dL if the subject is at a location with a high elevation)
  7. Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
  8. Known hypersensitivity to Clomid
  9. Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2 based on 0-4 scale or any trace of posterior subcapsular cataract)
  10. Abnormal fundoscopy exam such as central retinal vein occlusion
  11. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study
  12. Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, vasectomy, or tumors of the pituitary)
  13. Current or history of breast cancer
  14. Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA>3.6
  15. Presence or history of known hyperprolactinemia with or without a tumor
  16. Chronic use of medications such as glucocorticoids
  17. History of drug abuse or chronic narcotic use including methadone
  18. A recent history of alcoholism or illegal substance or steroid abuse (<2 years) or presence of moderate alcohol use (>21 drinks per week)
  19. Subjects with known history of HIV and/or Hepatitis C
  20. Subjects with end stage renal disease
  21. History of liver disease (including malignancy) or a confirmed AST or ALT >3 times the upper limit of normal
  22. History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia or know history of QTc interval prolongation
  23. History of cerebrovascular disease
  24. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism)
  25. History of erythrocytosis or polycythemia
  26. Subjects with cystic fibrosis (mutation of the CFTR gene)
  27. Subjects unable to provide a semen sample in a sponsor-approved clinic
  28. Enrollment in a previous Androxal study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01739595

United States, Alabama
Mobile, Alabama, United States, 36608
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Rancho Cucamonga, California, United States, 91730
United States, Florida
Bradenton, Florida, United States, 34208
Cooper City, Florida, United States, 33024
Coral Gables, Florida, United States, 33134
Miami Gardens, Florida, United States, 33169
United States, Kentucky
Lexington, Kentucky, United States, 40509
United States, New York
Rochester, New York, United States, 14609
United States, South Carolina
Mount Pleasant, South Carolina, United States, 29464
United States, Texas
Knoxville, Texas, United States, 37920
United States, Utah
Draper, Utah, United States, 84020
West Valley City, Utah, United States, 84120
Sponsors and Collaborators
Repros Therapeutics Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: Repros Therapeutics Inc. Identifier: NCT01739595     History of Changes
Other Study ID Numbers: ZA-302
Study First Received: November 29, 2012
Last Updated: October 22, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasm Metastasis
Endocrine System Diseases
Gonadal Disorders
Neoplastic Processes
Pathologic Processes
Estrogen Antagonists
Estrogen Receptor Modulators
Fertility Agents
Fertility Agents, Female
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Therapeutic Uses processed this record on May 21, 2015